13.79
price down icon0.92%   -0.175
 
loading

Uniqure N V (QURE) 最新ニュース

pulisher
Apr 23, 2025

UniQure stock holds $70 target, buoyed by FDA breakthrough nod - Investing.com Australia

Apr 23, 2025
pulisher
Apr 22, 2025

(QURE) Investment Analysis - news.stocktradersdaily.com

Apr 22, 2025
pulisher
Apr 21, 2025

Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha

Apr 21, 2025
pulisher
Apr 21, 2025

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Yahoo Finance

Apr 21, 2025
pulisher
Apr 21, 2025

uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold - Seeking Alpha

Apr 21, 2025
pulisher
Apr 21, 2025

uniQure: Bullish On Near Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha

Apr 21, 2025
pulisher
Apr 19, 2025

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha

Apr 19, 2025
pulisher
Apr 18, 2025

uniQure jumps on FDA breakthrough tag for Huntington’s disease drug - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

AMT-130 gets FDA breakthrough therapy designation - European Biotechnology Magazine

Apr 18, 2025
pulisher
Apr 18, 2025

FDA grants breakthrough status to uniQure’s Huntington’s therapy By Investing.com - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic By Stocktwits - Investing.com India

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic - MSN

Apr 17, 2025
pulisher
Apr 17, 2025

UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington's Disease Treatment - RagingBull

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure (QURE) Surges After FDA Grants Breakthrough Status to Gene Therapy - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure stock jumps on FDA breakthrough tag (QURE:NASDAQ) - Seeking Alpha

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure (QURE) Revenue and EPS Fall Short of Expectations - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure shares soar on FDA breakthrough therapy designation - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure shares soar on FDA breakthrough therapy designation By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

FDA grants breakthrough status to uniQure’s Huntington’s therapy - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure (QURE) Secures Breakthrough Therapy Status for AMT-130 | - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease | QURE Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease - TradingView

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure N.V. Receives FDA Breakthrough Therapy Designation for AMT-130 in Huntington's Disease Treatment - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure Announces FDA Breakthrough Therapy Designation - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease - Yahoo

Apr 17, 2025
pulisher
Apr 17, 2025

uniQure (NASDAQ:QURE) Shares Sold by Vanguard Group Inc. - Defense World

Apr 17, 2025
pulisher
Apr 17, 2025

Hemophilia B Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme Sanofi - Barchart.com

Apr 17, 2025
pulisher
Apr 16, 2025

uniQure CEO secures amended employment agreement By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 16, 2025

JPMorgan Chase & Co. Buys 58,246 Shares of uniQure (NASDAQ:QURE) - Defense World

Apr 16, 2025
pulisher
Apr 16, 2025

uniQure CEO secures amended employment agreement - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

uniQure Amends CEO Employment Agreement - TipRanks

Apr 16, 2025
pulisher
Apr 15, 2025

Alliancebernstein L.P. Has $3.60 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

NEVADA KING ANNOUNCES INCREASE OF PHASE III PROGRAM TO 30,000M, REFINES REGIONAL TARGETS AT ATLANTA - The Globe and Mail

Apr 14, 2025
pulisher
Apr 06, 2025

Institutional owners may ignore uniQure N.V.'s (NASDAQ:QURE) recent US$190m market cap decline as longer-term profits stay in the green - simplywall.st

Apr 06, 2025
pulisher
Apr 06, 2025

(QURE) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 02, 2025

uniQure (NASDAQ:QURE) Now Covered by Analysts at Chardan Capital - The AM Reporter

Apr 02, 2025
pulisher
Mar 31, 2025

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval - insights.citeline.com

Mar 31, 2025
pulisher
Mar 26, 2025

Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com

Mar 26, 2025
pulisher
Mar 25, 2025

Stock Watch: Are Gene Therapy Prices Too High For Success? - insights.citeline.com

Mar 25, 2025
pulisher
Mar 20, 2025

REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive®

Mar 20, 2025
pulisher
Mar 18, 2025

Dystrogen Therapeutics’ Cell Therapy DT-DEC01 Shows Long-Term Safety in Nonambulatory Duchenne Muscular Dystrophy - CGTLive®

Mar 18, 2025
pulisher
Mar 16, 2025

(QURE) Trading Report - Stock Traders Daily

Mar 16, 2025
pulisher
Mar 14, 2025

SpliceBio lauches Phase I/II study on dual-AAV-based therapy for Stargardt Disease - European Biotechnology Magazine

Mar 14, 2025
pulisher
Mar 13, 2025

uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 09, 2025

Oppenheimer & Co. Inc. Buys New Stake in uniQure (NASDAQ:QURE) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

FY2025 Earnings Estimate for uniQure Issued By HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

uniQure CFO Christian Klemt sells $107,407 in shares By Investing.com - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

uniQure Reports 2024 Financial Results and Progress - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure’s chief medical officer sells shares worth $13,891 - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure CFO Christian Klemt sells $107,407 in shares - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure’s chief medical officer sells shares worth $13,891 By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure CEO Matthew Kapusta sells shares worth $291,628 By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure chief legal officer sells shares for $72,812 By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

uniQure CEO Matthew Kapusta sells shares worth $291,628 - Investing.com

Mar 05, 2025
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
大文字化:     |  ボリューム (24 時間):